SIC
RYTM icon

SJS Investment Consulting’s Rhythm Pharmaceuticals RYTM Stock Holding History

SJS Investment Consulting’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22K Buy
+20
New +$1.81K ﹤0.01% 1734
2026
Q1 		– Sell
-2
Closed -$215 – 2557
2025
Q4 		$215 Buy
+2
New +$212 ﹤0.01% 1787

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SJS Investment Consulting's RYTM Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 20 shares worth $2.22K. The stake represents ﹤0.01% of the portfolio and ranks #1734 among its holdings. This is a return to the name: SJS Investment Consulting previously reported a position in RYTM as recently as Q4 2025.

SJS Investment Consulting first reported a position in RYTM in Q4 2025 and has held it in 2 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • SJS Investment Consulting held 20 shares of Rhythm Pharmaceuticals worth $2.22K as of Q2 2026.
  • Rhythm Pharmaceuticals was a new SJS Investment Consulting position in Q2 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1734 holding.
  • SJS Investment Consulting first reported a position in Rhythm Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.